Compugen (NASDAQ:CGEN) Coverage Initiated at Oppenheimer

Equities research analysts at Oppenheimer assumed coverage on shares of Compugen (NASDAQ:CGEN) in a note issued to investors on Monday, MarketBeat.com reports. The firm set an “outperform” rating and a $4.00 price target on the biotechnology company’s stock. Oppenheimer’s target price suggests a potential upside of 100.00% from the stock’s current price.

Compugen Stock Up 0.5 %

Shares of CGEN opened at $2.00 on Monday. Compugen has a twelve month low of $1.35 and a twelve month high of $3.03. The company has a market capitalization of $178.47 million, a P/E ratio of 100.00 and a beta of 2.59. The firm has a 50 day moving average of $1.58 and a 200 day moving average of $1.72.

Compugen (NASDAQ:CGEN) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.21 by ($0.20). The business had revenue of $17.13 million for the quarter, compared to analysts’ expectations of $17.67 million. Compugen had a net margin of 2.67% and a return on equity of 2.62%. During the same quarter in the prior year, the business posted ($0.11) earnings per share. On average, sell-side analysts expect that Compugen will post 0.11 EPS for the current year.

Institutional Trading of Compugen

A number of institutional investors have recently made changes to their positions in CGEN. Squarepoint Ops LLC raised its holdings in shares of Compugen by 23.4% during the second quarter. Squarepoint Ops LLC now owns 85,693 shares of the biotechnology company’s stock valued at $144,000 after purchasing an additional 16,253 shares during the last quarter. Joel Isaacson & Co. LLC grew its position in Compugen by 136.4% in the 3rd quarter. Joel Isaacson & Co. LLC now owns 52,000 shares of the biotechnology company’s stock worth $94,000 after purchasing an additional 30,000 shares during the period. Oppenheimer & Co. Inc. raised its stake in Compugen by 75.9% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 19,350 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 8,350 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Compugen by 82.7% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 274,335 shares of the biotechnology company’s stock valued at $497,000 after buying an additional 124,190 shares during the period. Finally, Atom Investors LP lifted its holdings in shares of Compugen by 27.5% during the 3rd quarter. Atom Investors LP now owns 151,816 shares of the biotechnology company’s stock valued at $275,000 after buying an additional 32,701 shares during the period. Hedge funds and other institutional investors own 12.22% of the company’s stock.

Compugen Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.